This antibody-cytokine fusion protein were generated fusing scIL12-scFvL19 to the CH4 domain of the IgE heavy chain (IL12-SIP (L19)), thus resulting in a homodimeric molecule comprising to antigen-binding sites. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EDB as well as the biological activity of IL12. The constructs This immunocytokine was designed for treating Advanced solid tumors, Advanced pancreatic cancer, Metastatic melanoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-001CQ-S(P) | Anti-Human FN1 Recombinant Antibody scFv Fragment (MOR03255) | ELISA, BL, IHC | Human antibody |
TAB-002CQ-S(P) | Anti-Human FN1 Recombinant Antibody scFv Fragment (ME-4C) | ELISA, IHC | Human antibody |
TAB-003CQ-S(P) | Anti-Human FN1 Recombinant Antibody scFv Fragment (1C5) | ELISA, WB | Human antibody |
TAB-071WM-S(P) | Anti-Human FN1 Recombinant Antibody scFv Fragment (CGS-1) | ELISA, WB | Human Antibody |
TAB-071WM-F(E) | Anti-Human FN1 Recombinant Antibody Fab Fragment (CGS-1) | ELISA, WB | Human Antibody |
There are currently no Customer reviews or questions for ACFP-SH088. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.